Begin typing your search above and press return to search.
Amid India-Canada diplomatic row
access_time 22 Sep 2023 4:00 AM GMT
K Radhakrishnan
access_time 21 Sep 2023 4:00 AM GMT
Womens quota in legislatures
access_time 20 Sep 2023 5:24 AM GMT
Extended Congress CWC meet raises hopes
access_time 19 Sep 2023 5:11 AM GMT
The saboteurs in the market of hate
access_time 18 Sep 2023 9:47 AM GMT
Schools breeding hatred
access_time 14 Sep 2023 10:37 AM GMT
access_time 16 Aug 2023 5:46 AM GMT
Remembering the Teachers
access_time 5 Sep 2023 6:24 AM GMT
Homechevron_rightTechnologychevron_rightMixed opinion by...

Mixed opinion by Indian experts on WHO's pause on HCQ trial


New Delhi: With the World Health Organisation deciding to temporarily drop hydroxychloroquine from its global study into experimental COVID-19 treatments, doctors in India are divided in their opinions over the repercussions the move might have on the strategy to combat the pandemic.

While some experts feel that after the WHO decisions, country's medical centres will have to take HCQ and chloroquine our of the treatment regimen of COVID-19 patients, others opined it is "not binding" for India to oblige with the decision of the world body.

"The Lancet study found out that people who were given HCQ or chloroquine or, combination of azithromycin with HCQ or chloroquine, matching with other factors, ran the risk of having higher mortality due to cardiac arrhythmia (irregular heartbeat)," city-based lung surgeon Dr Arvind Kumar said.

The study was done on nearly 15,000 patients, whose conditions were compared with those who weren't administered those drugs.

In a press briefing on Monday, WHO director-general Tedros Adhanom Ghebreyesus said that in light of a paper published last week in the Lancet that showed people taking hydroxychloroquine were at higher risk of death and heart problems, there would be "a temporary pause" on the hydroxychloroquine arm of its global clinical trial.

The WHO said that its experts need to review all available evidence to date.

As countries around the world explored the potential of hydroxychloroquine to treat COVID-19 patients, several experts earlier in May had sounded a note of warning to say it is not a wonder drug and may even be fatal in some cases.

After the fresh announcement by the WHO, while doctors like Kumar feel the anti-malarial drug will be taken out of the treatment regimen of COVID-19 patients, other medical experts said, India may take its own call on the HCQ.

Show Full Article
News Summary - Mixed opinion by Indian experts on WHO's pause on HCQ trial
Next Story